9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Incidence and Risk Factors of Oral Mucositis in Patients with Breast Cancer Who Receiving Chemotherapy in Al-Bashir Hospital

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Oral Mucositis (OM) remains the most common side effect of chemotherapy affects negatively on patients' quality of life.

          Subjects and Methods : Convenience samples of patients who received chemotherapy were followed from first or second cycle of chemotherapy until OM occurrence. We reviewed 75 female patients with breast cancer who received chemotherapy with mean age (47.2 SD ± 8.62861). We used WHO scale to assess the severity of OM. Demographic and other variables (age, number of cycle before appearance of signs of OM, WBC count, neutropenia count, creatinine and BMI) were filled in questionnaire.

          Results: 81.3% of reviewed patients were suffering from OM and (52.4%) of them were shown score 2 according to WHO classification, Taxane included chemotherapy protocol was the only significant variable that associated with OM occurrence (p=0.009).

          Conclusion: In this study; Taxane is the only risk factor that significantly associated with occurrence of OM.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions.

          A multitude of laboratory and clinical research studies of ulcerative oral mucositis induced by cytotoxic cancer therapies have been reported during the past decade. However, a comprehensive understanding of oral mucositis pathogenesis, together with a clear definition of risk factors for development and severity of the lesion, remain under investigation. The literature presents sometimes divergent data regarding these issues, which in turn restrict efforts to develop a unified approach for management of this morbid condition. The current review summarizes these controversies and highlights the need for strategies for stratification of patients enrolled in clinical trials, in relation to both pathophysiologic and associated risk factors. Copyright 2002 Elsevier Science Ltd.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Oral mucositis in cancer therapy.

            Oral mucositis induced by radiation therapy and chemotherapy is a frequently occurring toxicity in patients with cancer. Severe mucositis has a major impact on patient daily functioning,well-being, and quality of life. It can also compromise a patient's ability to tolerate planned therapy, resulting in missed doses or dose reductions. Mucositis negatively affects other health outcomes as well, increasing the risk of opportunistic infections and mortality due to sepsis. It also imposes a significant economic burden, since extended hospitalization and greater analgesic use can substantially increase treatment costs. A five-phase model of the pathobiology of mucositis has been proposed that facilitates our understanding of mucositis pathogenesis and the complex interactions that occur in response to tissue insult. Application of this evolving model has aided in the development of mechanistically based therapies for the prevention and treatment of mucositis. Continued research is needed to optimize when these treatments should be administered during the course of cancer therapy to maximize therapeutic benefit.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment.

              Chemotherapy- and radiotherapy-induced oral mucositis represents a therapeutic challenge frequently encountered in cancer patients. This side effect causes significant morbidity and may delay the treatment plan, as well as increase therapeutic expenses. The pathogenesis of this debilitating side effect can be attributed to the direct mucosal toxicity of cytotoxic agents and ionizing radiation and to indirect mucosal damage caused by a concomitant inflammatory reaction exacerbated in the presence of neutropenia, and the emergence of bacterial, mycotic, and viral infections. The prophylactic and therapeutic armamentarium for the treatment of oral mucositis consists of locally and systemically applied nonpharmacological measures and pharmacotherapeutics.
                Bookmark

                Author and article information

                Journal
                Int J Hematol Oncol Stem Cell Res
                Int J Hematol Oncol Stem Cell Res
                IJHOSCR
                International Journal of Hematology-Oncology and Stem Cell Research
                Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center (Tehran, Iran )
                2008-3009
                2008-2207
                1 October 2016
                : 10
                : 4
                : 217-223
                Affiliations
                [1 ]Clinical Oncology Resident Doctor, Clinical Oncology and Radiation Therapy Department, Al-Bashir Hospital, Al-Ashrafiyah, Amman, Jordan
                [2 ]Oncology Nurse Specialist, Clinical Oncology and Radiation Therapy Department, Al-Bashir Hospital, Al-Ashrafiyah, Amman, Jordan
                Author notes
                Corresponding Author: Ahmed A. Al Ibraheemi, MD. Clinical Oncology and Radiation Therapy Department, Al-Bashir Hospital, Al-Ashrafiyah, Amman, Jordan. Tel: +96264765115. Fax: +96264791000 dr.ahmed05@ 123456gmail.com
                Article
                IJHOSCR-10-217
                5139941
                27928476
                2c0e79bd-fefd-4285-90b8-6b6dffb623b2
                Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License, ( http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 25 April 2015
                : 6 October 2015
                Categories
                Original Article

                risk factors,oral mucositis,breast cancer,taxane
                risk factors, oral mucositis, breast cancer, taxane

                Comments

                Comment on this article